Denali Therapeutics Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. This is an annual report; quarterly figures below are included for Q4 context. Denali is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. It had no approved products and generated no product sales; reported revenue came from collaboration agreements.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Collaboration revenue | $26.7 million | $129.2 million |
| Research and development expense | $193.4 million | $143.2 million |
| General and administrative expense | $46.5 million | $32.3 million |
| Operating loss | $213.2 million | $46.4 million |
| Net loss | $197.6 million | $36.2 million |
| Net loss per share, basic and diluted | $2.07 | $0.39 |
| Cash used in operating activities | $151.6 million | Cash provided: $50.1 million |
- Revenue declined 79%, mainly because Denali recognized substantial Sanofi license revenue in 2018. FY2019 collaboration revenue included $20.8 million from Sanofi and $5.9 million from Takeda.
- Q4 2019 collaboration revenue was $4.7 million and net loss was $54.0 million, versus Q4 2018 revenue of $125.7 million and net income of $77.5 million. The prior-year quarter included significant Sanofi collaboration revenue; quarterly results are therefore not directly indicative of recurring performance.
- R&D expense rose 35%, reflecting advancement of clinical and preclinical programs, higher personnel costs, and facility expenses. G&A expense rose 44%, primarily from increased headcount and stock-based compensation.
- At year-end, cash, cash equivalents and marketable securities totaled $455.2 million, down from $612.2 million. Working capital was $384.7 million; total liabilities were $158.3 million. The filing reports no conventional borrowings; liabilities include operating lease obligations and collaboration contract liabilities.
- Operating cash use was $151.6 million. FY2018 operating cash inflow of $50.1 million reflected collaboration-related contract-liability inflows. FY2019 investing cash inflow of $147.7 million mainly reflected marketable-security maturities, not operating cash generation.
- Management said year-end liquidity was expected to fund projected operations for at least 12 months, subject to assumptions and spending changes. A January 2020 public offering subsequently generated approximately $194.1 million in net proceeds.
Material changes, outlook and notable items
- Denali reported 15 programs, with five in clinical studies as described in the filing. Its strategy emphasizes genetically supported targets, biomarker-led development and a blood-brain barrier transport-vehicle platform.
- DNL201 completed a Phase 1b Parkinson’s disease study in December 2019. The filing reported target and pathway biomarker engagement and a reduction in urinary BMP; safety findings included one severe headache leading to dose reduction and one withdrawal for headache and nausea. Management planned to select DNL201 or DNL151 for Phase 2/3 development after ongoing studies and toxicology work.
- DNL151 studies were ongoing, with higher-dose cohorts added; patient-study data were expected in mid-2020. DNL747 RIPK1 patient studies with Sanofi were ongoing, with next development decisions expected in mid-2020 based on safety, biomarker and toxicology data.
- The DNL310 Hunter syndrome IND was accepted in January 2020. Management planned to start a Phase 1/2 study in the first half of 2020 and seek patient biomarker proof of concept by year-end 2020. These are plans, not reported clinical outcomes.
- DNL343 entered a Phase 1 healthy-volunteer study in February 2020; initial safety and biomarker results were expected by late 2020. DNL593 remained in IND-enabling work, with an IND or CTA filing planned for 2021.
- Management expects significant losses and expenses to continue and does not expect product revenue in the near term. It anticipates rising development costs as programs advance. No earnings or revenue guidance was provided.
- Collaboration economics are conditional: Sanofi milestone payments could total approximately $1.1 billion and Takeda’s potential milestones depend on option exercises and future achievements. Denali also disclosed up to $447.0 million of contingent F-star payments tied to milestones; these uncertain future payments were not included in the contractual-obligations table.
- Key risks include clinical failure or delays, uncertain translation of biomarker results into clinical benefit, adverse effects or clinical holds, dependence on collaborators and contract manufacturers, competition, intellectual-property uncertainty, and the need for future financing. Denali previously discontinued DNL104 after liver-test abnormalities.
- The new headquarters lease created substantial long-term commitments: $107.5 million of undiscounted future lease payments, including $9.7 million due within one year; recorded operating lease liabilities were $72.5 million. No material litigation was reported.
- The financial statements received an unqualified audit opinion, as did internal control over financial reporting. The auditor identified collaboration-revenue recognition estimates—particularly forecast costs used to measure progress—as a critical audit matter.
Most important facts for investors to verify
- Whether the cash runway and post-year-end offering proceeds remain adequate relative to clinical-program spending and updated timelines.
- Whether ongoing LRRK2 and RIPK1 studies confirm safety and biomarker findings, and whether those findings translate into meaningful clinical outcomes.
- Whether DNL310 begins its planned patient study and produces interpretable biomarker results on the stated timeline.
- How collaboration revenue recognition, future milestone receipts, cost-sharing obligations and option decisions affect cash flow and reported revenue.
- The timing and likelihood of contingent license and acquisition payments, including the F-star milestones, and the effect of the headquarters lease on longer-term liquidity.